Phase 1 Startpositive

Phase 1 Start: A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an I

PARK overview →Track this catalyst
Drug
gb-5267
Indication
Platinum-resistant Ovarian Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 1 Start: A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an I — PARK Phase 1 Start | BioSniper